| Name | Title | Contact Details |
|---|
BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime`s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime`s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX.
ARLG addresses antibacterial resistance through innovative clinical trial design, unique access to clinically well-characterized bacteria, and opportunities for early-stage investigators.
Nautilus Environmental is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments.
Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.